Recent Updates
Recently added Catalysts
CODX Positive Sentiment Score: 75/100

Co-Diagnostics, Inc. to Host Booth at Senior Living Executive Conference in New Orleans, LA

Key Takeaway: Co-Diagnostics, Inc. is participating in the Argentum's 2023 Senior Living Executive Conference in New Orleans, showcasing its innovative Co-Dx PCR Home™ testing platform. The conference, running from May 8-10, is aimed at professionals in senior living, featuring over 750 exhibiting companies. Attendees can learn about Co-Diagnostics' pipeline for respiratory disease diagnostics, which includes tests for COVID-19, influenza, RSV, and tuberculosis. The Co-Dx PCR Home platform is currently under FDA review and is not yet available for sale.

Market Sentiment Analysis

POSITIVE FACTORS

  • Co-Diagnostics is showcasing innovative diagnostic solutions.
  • Participation in a major industry conference offers networking opportunities.
  • The upcoming Co-Dx PCR Home platform holds the potential for market expansion.

Full Press Release Details

SALT LAKE CITY, May 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at Argentum's 2023 Senior Living Executive Conference and Expo, being held May 8-10 in New Orleans, LA.
The conference is the official meeting of Argentum, the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living, and is described as an opportunity to connect with thousands of executives and experts in the senior living space, with over 750 exhibiting companies and thousands of participants.
The Company's booth will showcase Co-Diagnostics' upcoming Co-Dx PCR Home™ testing platform and its planned pipeline of respiratory disease diagnostics, including COVID-19, influenza, RSV and tuberculosis.
More information about the conference may be found here. Attendees interested in learning more about the Company and its upcoming Co-Dx PCR Home platform, which is subject to FDA review and is not available for sale, are invited to visit the Company's booth.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.
SOURCE Co-Diagnostics

21 %

more press release views with

Frequently Asked Questions

Where is the Argentum 2023 Senior Living Executive Conference held?

The conference takes place in New Orleans, LA from May 8-10, 2023.

What will Co-Diagnostics showcase at the conference?

Co-Diagnostics will showcase its Co-Dx PCR Home™ testing platform.

What diseases will the testing platform target?

The platform will target COVID-19, influenza, RSV, and tuberculosis.

Is the Co-Dx PCR Home™ platform available for sale?

No, the platform is subject to FDA review and is not yet for sale.

What is Co-Diagnostics, Inc. known for?

Co-Diagnostics specializes in developing molecular diagnostic technologies.

Last updated: May 9, 2023